Cantrixil Receives Orphan Drug Designation From FDA

Industry News

The FDA has granted CanTx’s chemotherapy candidate drug, Cantrixil, Orphan Drug Designation for the treatment of ovarian cancer.  CanTx is based in New Haven, CT and is a joint venture company between Yale University and Novogen (headquartered in Sydney, Australia).  The active ingredient in Cantrixil is TRXE-002, a small molecule cytotoxic drug candidate.  A cyclodextrin shell is used in Cantrixil to encapsulate TRXE-002.  Cantrixil is designed specifically for injection into the peritoneal and pleural cavities to deliver a cytotoxic effect in a non-irritant and non-toxic fashion.


Original Article:

Subscribe to WXPress

Receive our newsletter and information on upcoming events.